Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
23 Dec 2024

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

Dr James Martin - Cleveland Clinic, Cleveland, USA
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )
20 Dec 2024

The use of IORT at L'Hospitalet de Llobregat

Dr Evelyn Martínez Pérez - Catalan Institute of Oncology, Barcelona, Spain
The use of IORT at L'Hospitalet de Llobregat ( Dr Evelyn Martínez Pérez - Catalan Institute of Oncology, Barcelona, Spain )
19 Dec 2024

Understanding intraoperative radiation therapy for early stage breast cancer

Dr Jana Fox - Montefiore Medical Center, New York,USA
Understanding intraoperative radiation therapy for early stage breast cancer ( Dr Jana Fox - Montefiore Medical Center, New York,USA )
19 Dec 2024

The use of IORT at Montefiore Medical Center

Dr Sheldon Feldman - Montefiore Einstein Comprehensive Cancer Center, New York, USA
The use of IORT at Montefiore Medical Center ( Dr Sheldon Feldman - Montefiore Einstein Comprehensive Cancer Center, New York, USA )
19 Dec 2024

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC

Dr Nan Chen - The University of Chicago, Chicago, USA
Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC ( Dr Nan Chen - The University of Chicago, Chicago, USA )
19 Dec 2024

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival

Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK
Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival ( Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK )
19 Dec 2024

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
19 Dec 2024

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer

Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA
Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer ( Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA )
18 Dec 2024

Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer

Prof Robert Hills - University of Oxford, Oxford, United Kingdom
Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer ( Prof Robert Hills - University of Oxford, Oxford, United Kingdom )
18 Dec 2024

Breast conserving surgery and IORT can manage locally recurrent breast cancer

Dr Fabiana Gregucci - Weill Cornell Medicine, New York, USA
Breast conserving surgery and IORT can manage locally recurrent breast cancer ( Dr Fabiana Gregucci - Weill Cornell Medicine, New York, USA )
6 Dec 2024

Addressing Breast Cancer Disparities in Africa

Dr Paul Chilwesa - Population Health & Health Systems Strengthening Roche, Basel, Switzerland
Addressing Breast Cancer Disparities in Africa ( Dr Paul Chilwesa - Population Health & Health Systems Strengthening Roche, Basel, Switzerland )
6 Dec 2024